Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting
2021; Elsevier BV; Linguagem: Inglês
10.1016/j.jaip.2021.02.020
ISSN2213-2201
AutoresNicole Bavaro, Deborah Gakpo, Anisha Mittal, Jillian C. Bensko, Tanya M. Laidlaw, Kathleen M. Buchheit,
Tópico(s)Respiratory and Cough-Related Research
ResumoAspirin-exacerbated respiratory disease (AERD), the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase-1 inhibitors, is characterized by difficult-to-treat upper and lower respiratory symptoms. It is a type 2–mediated inflammatory disease marked by blood and tissue eosinophilia, dysregulated cysteinyl leukotriene production, and mast cell activation.1 Nasal polyposis in AERD is often severe and refractory to standard-of-care management including topical and systemic corticosteroids, endoscopic sinus surgery (ESS), and aspirin desensitization followed by high-dose daily aspirin.
Referência(s)